While this happened, Exane BNP Paribas initiated its Sanofi ADR [SNY] rating to an Outperform in a research note published on April 15, 2025; the price target was $65. A number of analysts have revised their coverage, including Goldman’s analysts, who began to cover the stock in late March with a ‘”a Neutral”‘ rating. Deutsche Bank also remained covering SNY and has increased its forecast on January 30, 2025 with a “Hold” recommendation from previously “Sell” rating. Argus maintained its rating on July 26, 2024. It rated SNY as “a Buy”.
Price Performance Review of SNY
On Monday, Sanofi ADR [NASDAQ:SNY] saw its stock fall -1.53% to $54.59. Over the last five days, the stock has gained 3.47%. Sanofi ADR shares have risen nearly 13.19% since the year began. Nevertheless, the stocks have risen 9.11% over the past one year. While a 52-week high of $60.12 was reached on 03/10/25, a 52-week low of $45.80 was recorded on 04/09/25. SMA at 50 days reached $54.76, while 200 days put it at $53.08.
Levels Of Support And Resistance For SNY Stock
The 24-hour chart illustrates a support level at 54.06, which if violated will result in even more drops to 53.52. On the upside, there is a resistance level at 55.21. A further resistance level may holdings at 55.82. The Relative Strength Index (RSI) on the 14-day chart is 54.94, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 1.90, which suggests price will go up in the next trading period. Percent R suggests that price movement has been bullish at 21.36%. Stochastics %K at 84.13% indicates the stock is a selling.
How much short interest is there in Sanofi ADR?
A steep rise in short interest was recorded in Sanofi ADR stocks on 2025-04-15, dropping by -1.66 million shares to a total of 3.95 million shares. Yahoo Finance data shows the prior-month short interest on 2025-03-14 was 5.61 million shares. There was a decline of -42.04%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 23, 2024 when Morgan Stanley began covering the stock and recommended ‘”an Equal-weight”‘ rating along with a $55 price target.
